Date de publication: 25 avril 2018
Promoteur – Intermédiaire Financier
BAVARIAN NORDIC A/SLieu
Description
This project will support Bavarian Nordic, a fully integrated Danish biotechnology company focused on the development, manufacturing and commercialisation of cancer immunotherapies and vaccines for infectious diseases. Financing is required for capital expenditure investments in Denmark.
Objectifs
The project supports the company's investments into a new fill-finish manufacturing facility. The investments cover the operational expenditure (OPEX) and capital expenditure (CAPEX) costs to construct, furnish and validate the new manufacturing facility to a commercial level. By co-investing in this project, the Bank contributes to fostering the generation of scientific knowledge and acumen within Europe, in addition to creating skilled employment opportunities.
Secteur(s)
- Industrie - Industrie manufacturière
Montant BEI envisagé (montant approximatif)
EUR 30 million
Coût total (montant approximatif)
EUR 98 million
Aspects environnementaux
The project falls under the annex II of the Environmental Impact Assessment (EIA) directive (2014/52/EU), referring to the manufacture of pharmaceutical products. The project has been screened by the competent authorities and there is no EIA required. Full environmental details will be assessed during the appraisal.
Passation des marchés
The promoter is a private company not operating in the utilities sector and is thus not covered by EU Directives on procurement.
Statut
Signé - 9/08/2018